Company News
Ernexa Therapeutics Stock Up 30% on Validation
Shares of Ernexa Therapeutics (NASDAQ:ERNA) rose about 30% on Wednesday after independent preclinical data confirmed efficacy of ERNA‑101 in ovarian cancer models.
The study found ERNA‑101 plus anti‑P
